drugset / Trial / NCT00162318
A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find a safe and effective dose of Erbitux and Iressa for subject with non small cell lung cancer.
Timeline
- Start
- 2005-03
- Primary completion
- 2006-04
- Completion
- 2006-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 100 mg/m2 | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 200 mg/m2 | Intravenous |
| Subject | Gefitinib | Small molecule | 250 mg | Oral |